ELX/TEZ/IVA

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

105 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

1

Ibsrela

AArdelyx

Phase 3

12

HSK31858

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

23

Myambutol

VVA Greater Los Angeles Healthcare System

Phase 2

24

Amoxil

GGlobal Antibiotics Research and Development Partnership

Phase 2

15

Tygacil

PPrism Pharmaceuticals

Phase 2

16

Trikafta

NNottingham University Hospitals NHS Trust

Phase 3

47

VNZ/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

18

ELX/TEZ/IVA

Vertex Pharmaceuticals

Phase 3

199

VX-121/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

410

Verapamil Hydrochloride

Mylan Pharmaceuticals Inc

Phase 3

1Show 31 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Cystic Fibrosis19 trials

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Completed·Vertex Pharmaceuticals·Phase 3·NCT04058353·271 enrolled

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older

Completed·Vertex Pharmaceuticals·Phase 3·NCT04183790·64 enrolled

VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)

Approved for marketing·Vertex Pharmaceuticals··NCT04058210

Show 16 more trials

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Completed·Vertex Pharmaceuticals·Phase 3·NCT05076149·597 enrolled

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Completed·Vertex Pharmaceuticals·Phase 3·NCT05033080·435 enrolled

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Completed·Vertex Pharmaceuticals·Phase 3·NCT05274269·307 enrolled

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Completed·Vertex Pharmaceuticals·Phase 3·NCT04545515·120 enrolled

ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation

Approved for marketing·Vertex Pharmaceuticals··NCT04702360

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

Completed·Vertex Pharmaceuticals·Phase 3·NCT04353817·121 enrolled

A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)

Completed·Vertex Pharmaceuticals·Phase 3·NCT05111145·86 enrolled

A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)

Completed·Vertex Pharmaceuticals·Phase 3·NCT04599465·69 enrolled

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Completed·Vertex Pharmaceuticals·Phase 3·NCT03691779·71 enrolled

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

Active, not recruiting·Vertex Pharmaceuticals·Phase 3·NCT06460506·50 enrolled

A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del

Completed·Vertex Pharmaceuticals·Phase 3·NCT04105972·176 enrolled

Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

Completed·Vertex Pharmaceuticals·Phase 3·NCT04537793·83 enrolled

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

Completed·Vertex Pharmaceuticals·Phase 3·NCT05153317·71 enrolled

A Phase 3 Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects With Non-F508del CFTR Genotypes

Active, not recruiting·Vertex Pharmaceuticals·Phase 3·NCT05331183·297 enrolled

A Phase 1 Study of VX-581 in Healthy Subjects and in Subjects With Cystic Fibrosis

Recruiting·Vertex Pharmaceuticals·Phase 1·NCT07283770·152 enrolled

A Phase 3, Open-label Study Evaluating the Pharmacokinetics, Safety, and Tolerability of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 12 to Less Than 24 Months of Age

Completed·Vertex Pharmaceuticals·Phase 3·NCT05882357·67 enrolled

Combination Therapy2 trials

A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy

Completed·Vertex Pharmaceuticals·Phase 3·NCT04362761·172 enrolled

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

Completed·Vertex Pharmaceuticals·Phase 3·NCT04043806·458 enrolled

Safety and Efficacy2 trials

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Completed·Vertex Pharmaceuticals·Phase 3·NCT04058366·251 enrolled

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Completed·Vertex Pharmaceuticals·Phase 3·NCT03525574·507 enrolled

Physical Activity1 trial

A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)

Completed·Vertex Pharmaceuticals·Phase 3·NCT04969224·82 enrolled

Details

Drug Info

Related News